多基因模型预测直肠癌术前放化疗后肿瘤反应性
本研究纳入184例接受术前放化疗后手术切除的局部晚期直肠癌患者,从福尔马林固定石蜡包埋肿瘤标本中分离候选基因mRNA,用NanoString nCounter基因表达检测分析,通过逐步逻辑回归筛选基因,建立基于FZD9、HRAS、ITGA7、MECOM、MMP3、NKD1、PIK3CD和PRKCB的多基因mRNA模型,该模型预测治疗反应的整体AUC为0.846,内部交叉验证AUC为0.808-0.909,且预测性能不受临床T或N分期、放疗与手术间隔及治疗前癌胚抗原水平影响(P = .001,95% CI,0.686-0.905)。
要点
- 建立含8个基因的mRNA模型预测直肠癌术前放化疗反应,整体AUC为0.846。
- 内部交叉验证3个队列AUC为0.808-0.909,预测稳定性较好。
- 模型预测性能不受临床T/N分期、放疗手术间隔及疗前CEA水平影响(P = .001)。
核心结论
- 开发了基于多基因mRNA的生物标志物模型,可预测直肠癌对术前放化疗的反应,可能有助于识别最受益于术前放化疗的患者。
研究设计与样本
- 纳入184例接受术前放化疗后手术切除的局部晚期直肠癌患者,分为良好反应者(完全或近完全消退)和不良反应者(其他所有患者)。
- 从福尔马林固定石蜡包埋肿瘤标本中分离候选基因mRNA,使用NanoString nCounter基因表达检测分析。
- 采用逐步逻辑回归分析在发现和训练阶段筛选基因,开发定量放疗反应性预测模型,并通过内部交叉验证组进行验证,以受试者工作特征曲线下面积(AUC)评估预测价值。
主要发现
- 通过比较良好与不良反应者的基因表达,构建了包含FZD9、HRAS、ITGA7、MECOM、MMP3、NKD1、PIK3CD和PRKCB的多基因mRNA模型。
- 该基因组预测治疗反应能力良好,整个数据集AUC为0.846。
- 内部交叉验证在3个队列中评估模型预测稳定性,AUC值为0.808-0.909。
- 放疗反应预测指数的诊断性能不受临床T或N分期、放疗与手术间隔及治疗前癌胚抗原水平等其他临床病理特征影响(P = .001,95% CI,0.686-0.905)。
关键数值与推荐
- 良好反应者定义为完全或近完全消退,不良反应者为其他所有患者。
- 多基因mRNA模型整体数据集AUC为0.846,内部交叉验证3个队列AUC为0.808-0.909。
- 模型预测性能不受临床T/N分期、放疗手术间隔及疗前CEA水平影响(P = .001,95% CI,0.686-0.905)。
临床怎么用
- 该多基因mRNA模型可用于预测局部晚期直肠癌患者对术前放化疗的反应,辅助识别最可能受益于术前放化疗的患者。
- 模型基于福尔马林固定石蜡包埋肿瘤标本的基因表达检测,具有临床转化潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although preoperative chemoradiotherapy (PCRT) is regarded as a standard treatment for locally advanced rectal cancer, there is no reliable biomarker for predicting responsiveness to PCRT. We aimed to develop a biomarker model for predicting response to PCRT. METHODS AND MATERIALS: We included 184 patients who received PCRT followed by surgical resection and categorized them as good responders (complete or near-complete regression) or poor responders (all other patients). Candidate gene mRNAs were isolated from formalin-fixed paraffin-embedded tumor specimens and analyzed using the NanoString nCounter gene expression assay. Stepwise logistic regression analysis was used to select genes in discovery and training phases. A quantitative radio-responsiveness prediction model was developed and validated using internal cross-validation groups, and the model's predictive value was assessed based on the area under the receiver operating characteristic curve (AUC). RESULTS: By comparing the gene expressions between good and poor responders, we created a multigene mRNA model using FZD9, HRAS, ITGA7, MECOM, MMP3, NKD1, PIK3CD, and PRKCB. This panel showed good ability to predict treatment response (AUC: 0.846 for the whole data set). Internal cross-validation was performed to evaluate the model's predictive stability among 3 cohorts, which provided AUC values of 0.808-0.909. The satisfactory diagnostic performance of the radio-response prediction index persisted regardless of other clinicopathologic features such as clinical T or N stage, interval between radiation and surgery, and pretreatment carcinoembryonic antigen levels (P = .001, 95% CI, 0.686-0.905). CONCLUSIONS: We developed a multigene mRNA-based biomarker model that allows prediction of rectal cancer response to PCRT, which may help identify patients who will benefit most from PCRT.
引用
- Cho E, Park IJ, Yeom SS, et al. A Multigene Model for Predicting Tumor Responsiveness After Preoperative Chemoradiotherapy for Rectal Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419511. doi:10.1016/j.ijrobp.2019.07.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。